ARTICLE | Clinical News
Plecanatide: Ph III data
December 30, 2016 1:20 AM UTC
Top-line data from a double-blind, North American Phase III trial in 1,054 patients with IBS-C showed that once-daily 3 and 6 mg oral plecanatide for 12 weeks each met the primary endpoint of improvin...
BCIQ Company Profiles
BCIQ Target Profiles